MEK1 and MEK2 inhibitors and cancer therapy: the long and winding road
The DOI matches its Crossref record; 201 of the 201 references it cites were found in a registry or an index.
Abstract
The role of the ERK signalling pathway in cancer is thought to be most prominent in tumours in which mutations in the receptor tyrosine kinases RAS, BRAF, CRAF, MEK1 or MEK2 drive growth factor-independent ERK1 and ERK2 activation and thence inappropriate cell proliferation and survival. New drugs that inhibit RAF or MEK1 and MEK2 have recently been approved or are currently undergoing late-stage clinical evaluation. In this Review, we consider the ERK pathway, focusing particularly on the role of MEK1 and MEK2, the 'gatekeepers' of ERK1/2 activity. We discuss their validation as drug targets, the merits of targeting MEK1 and MEK2 versus BRAF and the mechanisms of action of different inhibitors of MEK1 and MEK2. We also consider how some of the systems-level properties (intrapathway regulatory loops and wider signalling network connections) of the ERK pathway present a challenge for the success of MEK1 and MEK2 inhibitors, discuss mechanisms of resistance to these inhibitors, and review their clinical progress.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The limited ef fi cacy observed for MEK inhibitors may involve adaptive feedback mechanisms through the reactivation of MAPK signalling caused by the blockade of ERK signalling [11 -13].”
In the citing paper
“Although RAS/RAF-mutated CRC has been targeted for the development of therapeutic inhibitors, they have been largely ineffective, likely due to complex resistance mechanisms such as intrinsic and adaptive resistance [5–12].”
From An integrative gene expression signature analysis identifies CMS4 KRAS-mutated colorectal cancers sensitive to combined MEK and SRC targeted therapy (2022) · cites this paper as [5]
In the citing paper
“However, MEK inhibitors, used alone, have been largely ineffective, likely due to intrinsic and adaptive resistance mechanisms [5–7].”
From An integrative gene expression signature analysis identifies CMS4 KRAS-mutated colorectal cancers sensitive to combined MEK and SRC targeted therapy (2022) · cites this paper as [5]
In the citing paper
“Previous studies demonstrated that the adaptive reactivation of MAPK signaling in the presence of a MEK inhibitor was mediated by the loss of MAPK-dependent negative feedback loops and the consequent induction of RTKs signaling (26, 53).”
From New Horizons in KRAS-Mutant Lung Cancer: Dawn After Darkness (2019) · cites this paper as [53]
In the citing paper
“targeting of MEK alone is frequently hampered by adaptive resistance, which is complex and context-dependent, and can involve activation of various RTKs, including ERBB family, AXL, PDGFR-α, or FGFR1 (26, 53, 59–62).”
From New Horizons in KRAS-Mutant Lung Cancer: Dawn After Darkness (2019) · cites this paper as [53]
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
Untangling the ErbB signalling network
Yarden, Y., & Sliwkowski, M. X. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35052073 · Cited by 6,974
The ground state of embryonic stem cell self-renewal
Ying, Q.-L., Wray, J., Nichols, J., Batlle-Morera, L., Doble, B., Woodgett, J., Cohen, P., & Smith, A. (2008) · Nature · doi:10.1038/nature06968 · Cited by 3,442
Alessi, D. R., Cuenda, A., Cohen, P., Dudley, D. T., & Saltiel, A. R. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.46.27489 · Cited by 3,393
Identification of a Novel Inhibitor of Mitogen-activated Protein Kinase Kinase
Favata, M. F., Horiuchi, K. Y., Manos, E. J., Daulerio, A. J., Stradley, D. A., Feeser, W. S., Van Dyk, D. E., Pitts, W. J., Earl, R. A., Hobbs, F., et al. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.29.18623 · Cited by 3,015
Hauschild, A., Grob, J.-J., Demidov, L. V., Jouary, T., Gutzmer, R., Millward, M., Rutkowski, P., Blank, C. U., Miller, W. H., Kaempgen, E., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60868-x · Cited by 2,989
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations
Flaherty, K. T., Infante, J. R., Daud, A., Gonzalez, R., Kefford, R. F., Sosman, J., Hamid, O., Schuchter, L., Cebon, J., Ibrahim, N., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1210093 · Cited by 2,810
Cited by
Items 401–500 of 615
Distinct Prognostic and Immunological Roles of ETS1 and ETS2: A Pan‐Cancer Analysis
Ren, Y., Chen, B., & Zhang, M. (2023) · BioMed Research International · doi:10.1155/2023/4343350 · Cited by 9
“Discussion The RAS/MAPK pathway has been widely studied, and its constitutive activation has been observed frequently in a variety of cancers [14].”
BackgroundHartung, I. V., Hammer, S., Hitchcock, M., Neuhaus, R., Scholz, A., Siemeister, G., Bohlmann, R., Hillig, R. C., & Pühler, F. (2015) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2015.11.004 · Cited by 8
Demiroglu‐Zergeroglu, A., Ayvali, N., Turhal, G., Ceylan, H., & Baytaş, S. N. (2018) · Journal of Pharmacy and Pharmacology · doi:10.1111/jphp.13012 · Cited by 8
Wang, X., Wu, X., Xin, J., Li, S., Zheng, R., Guan, D., Gong, W., Zhao, Q., Wang, M., Chu, H., et al. (2020) · Archives of Toxicology · doi:10.1007/s00204-020-02771-w · Cited by 7
“MAP2K1, also known as MEK1, is a dual-specificity kinase which is involved in Ras/Raf/MEK/ERK pathway by activation of ERK1 and ERK2 (Caunt et al. 2015).”
BackgroundNichols, R. J., Haderk, F., Stahlhut, C. E., Schulze, C. J., Hemmati, G., Wildes, D. P., Tzitzilonis, C., Mordec, K., Marquez, A., Romero, J. M., et al. (2017) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/188730 · Cited by 7
Mudedla, S. K., Lee, H.-Y., Kim, J. J., Jang, S. H., Doddareddy, M. R., Sanam, S., Gundabathula, R., Park, J., & Wu, S. (2024) · ACS Omega · doi:10.1021/acsomega.4c03615 · Cited by 7
The safety and efficacy of binimetinib for lung cancer: a systematic review
Zahmatyar, M., Kharaz, L., Jahromi, N. A., Jahanian, A., Shokri, P., & Nejadghaderi, S. A. (2024) · BMC Pulmonary Medicine · doi:10.1186/s12890-024-03178-4 · Cited by 9
“…that MEK inhibitors in combination with BRAF inhibitors are better tolerated than are the respective monothera-pies; however, all MEK inhibitors in combination with standard-of-care cytotoxic chemotherapy increase toxicity, and there is a need for dose reduction or dosing schedule alteration [78].”
BackgroundLiu, Y., Ullah, I., Yuan, Y., & Wang, J. (2026) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2026.115776 · Cited by 7
Tracking and blocking interdependencies of cellular BRAF-MEK oncokinase activities
Fleischmann, J., Schwaighofer, S., Falco, L. D., Enzler, F., Feichtner, A., Kugler, V., Tschaikner, P., Huber, R. G., & Stefan, E. (2023) · PNAS Nexus · doi:10.1093/pnasnexus/pgad185 · Cited by 6
Xia, Z., Yang, Z., Dong, Y., Hao, X., Wang, K., Xia, W., Ren, L., Li, T., Xu, M., Zhu, G., et al. (2025) · International Journal of Biological Sciences · doi:10.7150/ijbs.104591 · Cited by 6
Vascular anomalies: Classification and management
Narsinh, K. H., Gautam, A., Baker, A., Cooke, D. L., & Dowd, C. F. (2020) · Handbook of clinical neurology · doi:10.1016/b978-0-444-64034-5.00003-1 · Cited by 8
Escape from G1 arrest during acute MEK inhibition drives the acquisition of drug resistance
Channathodiyil, P., May, K., Segonds-Pichon, A., Smith, P. D., Cook, S. J., & Houseley, J. M. (2022) · NAR Cancer · doi:10.1093/narcan/zcac032 · Cited by 6
“Consequently, the ERK1/2 pathway is a major target for drug development, and inhibitors of RAF and MEK are approved for treatment of melanoma, while ERK1/2 inhibitors are undergoing clinical trials; however, patients often relapse with drug-resistant tumours (7,8).”
BackgroundSelf-citationDevelopment of Erf-Mediated Craniosynostosis and Pharmacological Amelioration
Vogiatzi, A., Keklikoglou, K., Makris, K., Argyrou, D. S., Zacharopoulos, A. D., Sotiropoulou, V., Parthenios, N., Gkikas, A., Kokkori, M., Richardson, M. S. W., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24097961 · Cited by 6
“U0126, a specific MEK1/2 inhibitor but low potency drug [38,39], was used with encouraging results in the treatment of an FGFR2-induced craniosynostosis mouse model [7], and we have shown that it can effectively regulate Erf localization and function [14].”
ResultChen, X., Zhong, Y., Wang, S., Xu, S., Chen, J., Cheng, X., & Yang, X. (2024) · Journal of bone oncology · doi:10.1016/j.jbo.2024.100601 · Cited by 6
“MEK has become an essential cancer treatment strategy due to its central position and significance [18].”
BackgroundOsumi, H., Muroi, A., Sakahara, M., Kawachi, H., Okamoto, T., Natsume, Y., Yamanaka, H., Takano, H., Kusama, D., Shinozaki, E., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-74530-x · Cited by 6
Combinatorial approaches for mitigating resistance to KRAS-targeted therapies
Warren, H. R., Ross, S. J., Smith, P. D., Coulson, J. M., & Prior, I. A. (2022) · Biochemical Journal · doi:10.1042/bcj20220440 · Cited by 8
“…and ARS1620 that target the mutant protein but spare wild-type KRAS [24], the KRAS antisense oligonucleotide inhibitor AZD4785 [25] that will target both wild type and mutant KRAS, and the MEK1/MEK2 inhibitor selumetinib (AZD6244/ARRY-142866) [26,27] that targets a key downstream effector of KRAS.”
Self-citationRAF inhibitors activate the integrated stress response by direct activation of GCN2
Gilley, R., Kidger, A. M., Neill, G. W., Morrison, E., Severson, P. L., Byrne, D. P., Kenneth, N. S., Bollag, G. E., Zhang, C., de Oliveira, T. M., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-65376-w · Cited by 11
Self-citationLi, M., Lu, M., Wang, L., Zhang, Y., Yan, L., Wang, S., & Peng, T. (2025) · Chemical Science · doi:10.1039/d5sc08317f · Cited by 5
Insights into RAS-driven melanoma and its therapeutic implications
Chatziioannou, E., Lallas, K., Sinnberg, T. W., Niessner, H., Stratigos, A., Flatz, L., & Amaral, T. (2026) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2026.103090 · Cited by 7
Matsuda, A., Masuzawa, R., Takahashi, K., Takano, K., & Endo, T. (2024) · Cytoskeleton · doi:10.1002/cm.21881 · Cited by 6
Reversible control of kinase signaling through chemical-induced dephosphorylation
Sun, Y., Zhou, R., Hu, J., Feng, S., & Hu, Q. (2024) · Communications Biology · doi:10.1038/s42003-024-06771-9 · Cited by 6
“The dual-speci fi city kinases MEK1 and MEK2 are at the center of the RAF-MEK-ERKsignalingpathway 52 .”
BackgroundDynamic and structural insights into allosteric regulation on MKP5 a dual-specificity phosphatase
Skeens, E., Maschietto, F., Manjula, R., Shillingford, S. R., Murphy, J., Lolis, E., Batista, V. S., Bennett, A. M., & Lisi, G. P. (2025) · Nature Communications · doi:10.1038/s41467-025-62150-w · Cited by 6
Kambaru, A., & Chaudhary, N. (2021) · Current Pharmaceutical Biotechnology · doi:10.2174/1389201022666210810094739 · Cited by 5
Santos, J., da Silva, S. P., Bastos, M. M. S. M., Oliveira, P. A., da Costa, R. M. G., & Medeiros, R. (2022) · Journal of Physiology and Biochemistry · doi:10.1007/s13105-021-00866-1 · Cited by 5
“Cyclin D1 or Ccnd1 is involved in the cell cycle, and in spite of being a target of let-7b, its expression is also regulated by ERK and p38 pathways at the transcriptional level [6, 14].”
BackgroundWilhelm, T., Toledo, M. A. S., Simons, I., Stuth, C., Mohta, V., Mülfarth, R. I., Nitsche, M., Maschke-Neuss, K., Schmitz, S., Kaiser, A., et al. (2022) · Hematological Oncology · doi:10.1002/hon.3100 · Cited by 5
“inhibitor/MEK molecule ratio, provoked by cellular resistance mechanisms or missing patient compliance, can then cause vehement re‐activation of the MEK/ERK pathway.(17) MEK inhibitors of a newer generation, like Trametinib (GSK 1120212; JTP‐74057), alter”
BackgroundThe dichotomy of regulatory B cells in cancer versus allergic disease
Dang, M., Yu, J., Galant-Swafford, J., & Karam, S. D. (2023) · Molecular Carcinogenesis · doi:10.1002/mc.23633 · Cited by 6
BRAF Non-V600 Mutations in Metastatic Colorectal Cancer
Liu, J., & Xie, H. (2023) · Cancers · doi:10.3390/cancers15184604 · Cited by 5
“Trametinib (also known as Mekinist) dimethyl sulfoxide is an allosteric inhibitor of MEK1 and MEK2 proteins [50].”
Iterative machine learning-based chemical similarity search to identify novel chemical inhibitors
Durai, P., Lee, S. J., Lee, J. W., Pan, C., & Park, K. (2023) · Journal of Cheminformatics · doi:10.1186/s13321-023-00760-6 · Cited by 6
The RAS-Regulated RAF-MEK1/2-ERK1/2 Protein Kinase Pathway: The Path Most Traveled in RASopathies
Dutkiewicz, R., Sharpe, H. J., & Cook, S. J. (2024) · Springer eBooks · doi:10.1007/978-3-031-62945-7_18 · Cited by 5
Self-citationCaunt, C. J., Kidger, A. M., & Keyse, S. M. (2016) · Methods in molecular biology · doi:10.1007/978-1-4939-3746-2_12 · Cited by 6
Self-citationMEK1 is required for the development of NRAS-driven leukemia
Nowacka, J. D., Baumgartner, C., Pelorosso, C., Roth, M., Zuber, J. A., & Baccarini, M. (2016) · Oncotarget · doi:10.18632/oncotarget.12555 · Cited by 6
“To date, only a few mutations that increase the activity of MEK1 have been described in ovarian cancer, lung cancer, melanoma and colon cancer (recently reviewed in [11]).”
BackgroundMaik-Rachline, G., Cohen, I., & Seger, R. (2018) · Resistance to targeted anti-cancer therapeutics · doi:10.1007/978-3-319-67932-7_5 · Cited by 6
Cancer Mutations: Molecular MEKanisms
Bardwell, L. (2020) · Current Biology · doi:10.1016/j.cub.2020.01.039 · Cited by 5
Pasdaran, A., Grice, I. D., & Hamedi, A. (2024) · Drug Development Research · doi:10.1002/ddr.22180 · Cited by 6
Role of MEK1 in TLR4 Mediated Signaling
Bauerfeld, C. P., & Samavati, L. (2017) · Journal of Cell Signaling · doi:10.4172/2576-1471.1000135 · Cited by 6
“In this regard MEK1/2 is exquisitely specific, whereas ERK can activate hundreds of substrates [14].”
Learning Single-Cell Perturbation Responses using Neural Optimal TransportPreprint
Bunne, C., Stark, S. G., Gut, G., del Castillo, J. S., Levesque, M. P., Lehmann, K.-V., Pelkmans, L., Krause, A., Rätsch, G., & * (2022) · Research Square · doi:10.21203/rs.3.rs-1805107/v1 · Cited by 5
Zheng, J., Lu, W., Wang, C., Chen, S., Zhang, Q., & Su, C. (2024) · Aging · doi:10.18632/aging.205974 · Cited by 5
Vasudevan, H. N., Arang, N., Nunez, M. S., Kennedy, P., Payne, E., Mohabeer, S., Chien, J., Wright, A., Sale, M. J., Krogan, N. J., et al. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2506823122 · Cited by 6
“The MEK inhibitors selumetinib ( 4 , 17 ) and mirdametinib ( 5 ) demonstrate clinical efficacy for NF1 mutant pNFs, yet resistance to MEK inhibition often arises through feedback reactivation of RAF/MEK/ERK signaling ( 21 ).”
Self-citationTrametinib in Adults with Neurofibromatosis Type 1‐Related Symptomatic Plexiform Neurofibromas
Noordhoek, D. C., Hanff, D. F., French, P. J., van Dijk, S. A., Wiemer, E. A. C., Manintveld, O. C., van den Bent, M. J., & Taal, W. (2025) · Annals of Neurology · doi:10.1002/ana.78010 · Cited by 4
“32,33 Our study has some limitations.”
Abdulmalek, S. A., Mahmoud, F. A., Awad, D., Saleh, A. M., Elkady, A. I., Ghareeb, D. A., & Balbaa, M. (2025) · Discover Oncology · doi:10.1007/s12672-025-03714-6 · Cited by 4
“Notably, inhibitors targeting Raf and MEK have received regulatory approval for their use in clinical settings [10].”
Targeting MEK in cancer and beyond: mechanistic insights and therapeutic opportunities
Chan, W. Y., da Silva, I. P., Long, G. V., & Rizos, H. (2026) · The Lancet · doi:10.1016/s0140-6736(26)00199-6 · Cited by 6
Evaluation of Delayed-Type Hypersensitivity to Antineoplastic Drugs—An Overview
Roger, I., Montero, P., Pérez‐Leal, M., Milara, J., & Cortijo, J. (2023) · Cancers · doi:10.3390/cancers15041208 · Cited by 5
p38 mitogen-activated protein kinase inhibitors
El‐Damasy, A. K., Salem, M. S. H., Sebaiy, M. M., & Elgawish, M. S. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-96121-9.00011-5 · Cited by 4
Yang, M., Nebozhyn, M., Schell, M. J., Gandhi, N. S., Pflieger, L. T., Loboda, A. P., Pledger, W. J., Soundararajan, R., Maurin, M. M., Wang, H., et al. (2025) · BMC Cancer · doi:10.1186/s12885-025-13829-2 · Cited by 5
“KRAS/ BRAF -mutated CRC has been targeted but therapeutic inhibitors are largely ineffective, likely due to complex resistance mechanisms that are not well understood [22, 30, 31].”
Vuaroqueaux, V., Musch, A., Peille, A.-L., Kelter, G., Weichert, L., Metz, T., Hendriks, H. R., & Fiebig, H. (2023) · Cancer Research Communications · doi:10.1158/2767-9764.crc-22-0221 · Cited by 4
“…RAS-RAF and ERK in the oncogenic MAPK signaling pathway, MEK 1 and 2 are among the most attractive targets for the treatment of a broad range of cancer types (melanoma, thyroid, large part of tumors of the digestive and urogenital systems) carrying RAF or RAS -activating alterations (17–19).”
BackgroundZheng, B., Zhang, S., Cai, W., Wang, J., Wang, T., Tang, N., Shi, Y., Luo, X., & Yan, W. (2019) · Cancer Genomics & Proteomics · doi:10.21873/cgp.20144 · Cited by 6
Mazzera, L., Abeltino, M., Lombardi, G., Cantoni, A. M., Jottini, S., Corradi, A., Ricca, M., Rossetti, E., Armando, F., Peli, A., et al. (2023) · Leukemia · doi:10.1038/s41375-023-01940-x · Cited by 5
“A Western blot analysis of endogenous phospho-ERK1/2 (Thr202/Tyr204), ERK1/2, phospho-BCR::ABL1 (Tyr412), BCR::ABL1, phospho-ABL1 (Tyr412), phospho-ABL1 (Thr735), ABL1, phospho-CrkL (Tyr207), CrkL and Actin in Ba/F3p210 T315I , Imatinib-resistant Ph + cell lines and primary cells derived from patients with Ph + leukem…”
InfluentialRetractedMechanism of Abnormal Activation of MEK1 Induced by Dehydroalanine Modification
Zhao, Y., Du, S.-S., Zhao, C., Li, T., Tong, S.-C., & Zhao, L. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25137482 · Cited by 4
Identification of neuronal autophagy regulators: Combined use of iKAP and THANATOS
Chen, L., & Xie, J. (2018) · Movement Disorders · doi:10.1002/mds.27354 · Cited by 4
“of cancer.(3) However, autophagy is attenuated by the inhibition of MAP2K2,(4) indicating that MAP2K2 may play a different role in neurodegenerative diseases.”
BackgroundA Bayesian Random Partition Model For Sequential Refinement and Coagulation
Zanini, C. T. P., Müller, P., Ji, Y., & Quintana, F. A. (2019) · Biometrics · doi:10.1111/biom.13047 · Cited by 4
“, 2016); and mitogen-activated protein kinase kinase (MEK), which is an important component of the ERK1/2 signaling pathway that is often deregulated in cancer cells (Caunt et al., 2015).”
BackgroundStructurally-informed human interactome reveals proteome-wide perturbations by disease mutationsPreprint
Xiong, D., Qiu, Y., Zhao, J., Zhou, Y., Lee, D., Gupta, S., Torres, M., Lü, W., Liang, S., Kang, J. J., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.04.24.538110 · Cited by 4
Repurposing bosentan as an anticancer agent: EGFR/ERK/c‐Jun modulation inhibits NSCLC tumor growth
Khalaf, M. M., Malak, M. N., Alsahli, T. G., Althobaiti, M. M., Hamzawy, M. A., & Abdel‐Fattah, M. M. (2025) · Fundamental and Clinical Pharmacology · doi:10.1111/fcp.13052 · Cited by 4
“Substantial bodies of evidence have supported the utility of this pathway and its inhibitors for targeting cancer treatment [9 – 11].”
Ding, C., Guo, J., Wang, C., & Li, H. (2025) · Fitoterapia · doi:10.1016/j.fitote.2025.106819 · Cited by 3
Khan, M. S., Shamsi, A., Zuberi, A., & Shahwan, M. J. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1619639 · Cited by 3
“As such, this enzymatic activity renders MEK1 a pivotal therapeutic target in cancers with mutations that constitute this pathway (Caunt et al., 2015).”
Tirpe, A., Nutu, A. M., Busuioc, C. I., Pop, O. L., & Berindan‐Neagoe, I. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1677471 · Cited by 5
“In its turn, ERK1/2 phosphorylates downstream effectors, which modulate cell survival, proliferation, differentiation, and cell motility (71).”
Chaudhary, H. A., Cannon, T. L., & Winer, A. (2024) · Drugs in R&D · doi:10.1007/s40268-024-00475-5 · Cited by 4
Identifying Novel Genetic Markers in Pediatric Rhabdomyosarcoma
Xu, J., Wang, T., & Burjonrappa, S. C. (2024) · Journal of Pediatric Surgery · doi:10.1016/j.jpedsurg.2024.161928 · Cited by 3
Nicol, É., Do, B., Vignes, M., Annereau, M., Paul, M., Wolkenstein, P., Touboul, D., & Secrétan, P.-H. (2024) · Pharmaceutical Development and Technology · doi:10.1080/10837450.2024.2405829 · Cited by 3
“However, pharmacological approaches are evolving, with mitogen-activated extracellular signal-regulated protein kinase (MEK) inhibitors like selumetinib (Caunt et al. 2015) showing promise in clinical trials for NF1-related plexiform neurofibromas (Gross et al. 2020).”
Weiss, L., Zhang, D., Kunz, W. G., Boeck, S. H., Curigliano, G., Subbiah, V., Lordick, F., Brummer, T., Westphalen, C. B., & Bielo, L. B. (2025) · ESMO Gastrointestinal Oncology · doi:10.1016/j.esmogo.2024.100129 · Cited by 5
“28 Several types of mutations involving BRAF can lead to its oncogenic activation, categorized within three distinct classes (class I-III).”
The Role of the Mitogen-Activated Protein Kinase (MAPK) Signaling Pathway in Cancer
Lotfaliansaremi, S., Sabio, M. L., Comwell, S., & Tolias, P. P. (2020) · Medical Research Archives · doi:10.18103/mra.v8i4.2086 · Cited by 5
Cancer - dysregulation of the cell cycle and transduction of cascade signals
Madaminov, А. Y., Khasanov, A. I., Khatamov, S., Abdurakhmonov, O., Amonov, A., Shukurov, Z., Khudayorov, M., Bekmirzaev, R., & Нишонбоев, Л. (2021) · Romanian Journal of Rhinology · doi:10.2478/rjr-2021-0017 · Cited by 3
Tan, E. Y., Chiparus, O., Choudhury, S., Kim, C., Lau, M. R., Ziltener, C., & Ilankumaran, P. (2022) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.1129 · Cited by 3
Cytosolic EpCAM cooperates with H-Ras to regulate epithelial to mesenchymal transition through ZEB1
Omar, F. A., Brown, T. C., Gillanders, W. E., Fleming, T. P., Smith, M. A., Bremner, R. M., & Sankpal, N. V. (2023) · PLoS ONE · doi:10.1371/journal.pone.0285707 · Cited by 3
“This is in agreement with reports in which MEK inhibitor monotherapy demonstrated modest efficacy due to transcription of negative feedback genes and the activation of PI3K-AKT survival pathway [54].”
ResultGómez‐Millán, J., Pajares, B., Pérez-Villa, L., Carnero, A., Álvarez, M., de Luque, V., Rivas‐Ruiz, F., Trigo, J. M., Toledo, M. D., Alba, E., et al. (2016) · BMC Cancer · doi:10.1186/s12885-016-2869-x · Cited by 3
“In the MAPK pathway, MEK1 and MEK2 are the only activators of ERK2, processing inputs from multiple upstream kinases [10].”
Metrock, L. K., Lobbous, M., & Korf, B. R. (2021) · Expert Review of Precision Medicine and Drug Development · doi:10.1080/23808993.2021.1917989 · Cited by 3
Association of bilateral pan-uveitis with the use of trametinib for Langerhans cell histiocytosis.
Du, Y., & Hu, Y. (2022) · PubMed · Cited by 3
Hafner, M. A., Mills, C. E., Subramanian, K., Chen, C., Chung, M., Boswell, S. A., Everley, R. A., Liu, C., Walmsley, C. S., Juric, D., et al. (2017) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/211680 · Cited by 3
SHP2 Inhibition Abrogates MEK inhibitor Resistance in Multiple Cancer ModelsPreprint
Fedele, C., Ran, H., Diskin, B., Wei, W., Jen, J., Araki, K. Y., Simeone, D. M., Miller, G., Neel, B. G., & Tang, K. H. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/307876 · Cited by 3
Structural and Molecular Determinants of CCS-Mediated Copper Activation of MEK1/2Preprint
Grasso, M. J., Bond, G. J., Kim, Y., Alwan, K. B., Boyd, S. D., Dzebo, M. M., Valenzuela, S., Tsang, T., Schibrowsky, N. A., Matthews, M. L., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.05.01.072124 · Cited by 3
“The vital importance of intricate mechanisms to dynamically regulate MAPK signaling output is underscored by its dysregulation in approximately 85% of human cancers(Caunt et al., 2015; Holderfield et al., 2014).”
BackgroundMultidimensional single-cell modeling of cellular signalingPreprint
Wade, J. D., Lun, X., Bodenmiller, B., & Voit, E. O. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.11.15.383711 · Cited by 3
“…function of ERK pathway components is deregulated in many cancers, the pathway is a common target of cancer drugs (Samatar and Poulikakos, 2014; Caunt et al., 2015), and cell-to-cell variation has limited the success of these targeted therapies (Wellbrock and Arozarena, 2016; Caunt et al.,…”
BackgroundSiahmazgi, Z. G., Irani, S., Ghiaseddin, A., Soutodeh, F., Gohari, Z., Afifeh, J., Pashapour‐Yeganeh, A., Samimi, H., Naderi, M., Fallah, P., et al. (2024) · Research in Pharmaceutical Sciences · doi:10.4103/rps.rps_38_24 · Cited by 3
Kim, H. K., Kim, S. J., Gil, W. J., & Yang, C. (2025) · Chemical Engineering Journal · doi:10.1016/j.cej.2025.169109 · Cited by 2
Synthesis and anticancer potential of glycosides
Ali, S., Rukh, G., Ogaly, H. A., Ajaj, R., Rauf, A., & Shah, S. A. A. (2025) · RSC Advances · doi:10.1039/d5ra07626a · Cited by 2
“In addition, compound 69 was treated with D -glucose and iodine in acetic acid at room temperature, forming C -glycoside imidazo [4,5-d ]thiazole derivative 70 , which was protected with acetic anhydride and pyridine under re ux conditions to provide protected glycosides 71 .”
Ribosome biogenesis as a potential therapeutic target in KRAS mutant colorectal cancer
Tanaka, Y., Sakahara, M., Yamanaka, H., Natsume, Y., Kusama, D., Kumegawa, K., Yoshikawa, H., Abe, Y., Okabayashi, K., Matui, S., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-67979-9 · Cited by 4
Yue, W., Wu, Z., Zhang, K., Long, W., Cui, J., Li, A., & Fang, Y. (2026) · Cell Reports · doi:10.1016/j.celrep.2026.116931 · Cited by 3
Li, C., Deng, S., Zhuang, M., Li, T., Lin, L., Zheng, L., Lin, K., Li, D., & Chen, F. (2026) · Oncogene · doi:10.1038/s41388-026-03795-9 · Cited by 2
“Huge efforts have been made to block this pathway by targeting EGFR [4, 5], RAS [6, 7], RAF [8, 9], and MEK [10 – 12].”
Sensitivity of Oncogenic KRAS-Expressing Cells to CDK9 Inhibition
Lai, L., Brel, V., Sharma, K., Frappier, J., Le-Henanf, N., Vivet, B., Muzet, N., Schell, E., Morales, R., Rooney, E. K., et al. (2021) · SLAS DISCOVERY · doi:10.1177/24725552211008853 · Cited by 2
Shen, X., Wang, Y., Yin, K., Wang, F., Miao, C., Sheng, J., & Liu, D. (2022) · Journal of Food Processing and Preservation · doi:10.1111/jfpp.16929 · Cited by 2
Reporter cell lines to screen for inhibitors or regulators of the KRAS-RAF-MEK1/2-ERK1/2 pathway
Weatherdon, L., Stuart, K., Cassidy, M. A., de la Gándara, A. M., Okkenhaug, H., Muellener, M., McKenzie, G. J., Cook, S. J., & Gilley, R. (2024) · Biochemical Journal · doi:10.1042/bcj20240015 · Cited by 2
“BRAF and MEK inhibitors (BRAFi and MEKi) are now approved for the treatment of BRAF V600E/K melanoma [9,10] and colorectal cancer [11]; the MEKi, Selumetinib, is approved for the treatment of paediatric neuro fi bromatosis, a RASopathy driven by deregulated RAS activation [12] and ERK1/2 inhibitors…”
BackgroundSelf-citationDysregulated Gab1 signalling in triple negative breast cancer
Bongartz, H., Mehwald, N., Seiß, E. A., Schumertl, T., Naß, N., & Dittrich, A. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-024-01542-9 · Cited by 2
“One reason for this is the development of resistance (for review, see [17, 19, 40]).”
BackgroundGong, K.-Q., Brune, J. E., Guo, X., & Manicone, A. M. (2024) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00080.2024 · Cited by 2
Chen, H., Xie, S., Zhou, Y., Chen, L., Xu, J., & Cai, J. (2024) · Biochemical Pharmacology · doi:10.1016/j.bcp.2024.116572 · Cited by 2
Andersen, M. D., Wolter, K., Enemark, M. B., Lauridsen, K. L., Hamilton-Dutoit, S. J., Starklint, J., d’Amore, F., Ludvigsen, M., Honoré, B., & Kamper, P. (2024) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2024.2434170 · Cited by 2
“MEK, activated by upstream mutations in cancer, is used as a drug target in, e.g. melanomas, pancreatic cancer, non-small cell lung cancer, and acute myeloid leukemia [27,31].”
Cook, S. J. (2024) · Journal of Clinical Oncology · doi:10.1200/jco-24-02375 · Cited by 2
Self-citationChen, S.-D., Zhang, C., Huang, H., Wang, Y., Lian, M., & Hong, G. (2025) · Journal of Molecular Histology · doi:10.1007/s10735-024-10342-x · Cited by 2
“Targeted therapeutic agents have modestly reduced side effects and improved survival rates (Holderfield et al. 2014; Caunt et al. 2015); however, the availability of effective drugs is limited, and their therapeu - tic efficacy requires further optimization.”
Alotaibi, H. A., Yuen, H. K. L., Alshaibani, A. K., & Alibrahim, E. A. (2025) · Orbit · doi:10.1080/01676830.2025.2470989 · Cited by 2
“14,15,30 Interestingly, Dombi et al. 14 highlighted the fact that the patients who showed a favorable response were 75% of the 20 mg per square meter group, 83% of the 25 mg per square meter group, and 50% of the 30 mg per square meter group, demonstrating that increasing the dose is not always…”
Role of MEK1 and DIAPH3 Expression in Colorectal Carcinoma
Foda, A. A.-R. M., Ahmed, M. A. H., Elkalla, H., Elzahaf, E., Abdallah, H. M., Wagih, H. M., & Sami, M. M. (2018) · Research in Oncology · doi:10.21608/resoncol.2018.4042.1059 · Cited by 2
Kinase perturbations redirect mitochondrial function in cancer
Torres‐Quesada, O., Strich, S. L., & Stefan, E. (2022) · Bioenergetics Communications · doi:10.26124/bec:2022-0013 · Cited by 3
“In contrast, MEK inhibitors target wild-type proteins (Caunt et al 2015).”
BackgroundRole of MEK1 and DIAPH3 expression in colorectal adenoma-carcinoma sequence
Foda, A. A.-R. M., El-Hawary, A. K., Elnaghi, K., Eldehna, W. M., & Enan, E. T. (2024) · Tumor Biology · doi:10.3233/tub-230038 · Cited by 3
Discovering the effect of combination of celecoxib and sorafenib on hepatocellular carcinoma
Gu, W., Zeng, D., & Zhang, C. (2024) · Discover Oncology · doi:10.1007/s12672-024-01203-w · Cited by 2
New Challenges in Cancer Therapy: MAPK Inhibitors from Bench to Bedside
Ropert, C., & Huth, H. W. (2017) · Springer eBooks · doi:10.1007/978-3-319-53082-6_3 · Cited by 1
Molecular Pathology and Genomics of Melanoma
Griewank, K., Murali, R., & Wiesner, T. (2018) · Springer eBooks · doi:10.1007/978-3-319-46029-1_41-1 · Cited by 2
Network and Computational Drug Repurposing Analysis for c-Myc Inhibition in Burkitt Lymphoma
LEE, Y., & Nam, S. (2023) · Cancer Genomics & Proteomics · doi:10.21873/cgp.20418 · Cited by 1
Reeder, T. L., Zarlenga, D. S., Ziegler, A. L., & Dyer, R. M. (2024) · Journal of Dairy Science · doi:10.3168/jds.2023-24578 · Cited by 1
Design and Synthesis of Novel MEK Inhibitors for the Treatment of Solid Tumors
Zeng, J., Luo, Z., Zhao, T., Xia, C., Liu, F., Li, N., Qu, L., & Wang, C. (2025) · Chemical Biology & Drug Design · doi:10.1111/cbdd.70067 · Cited by 1
“…are limited in their clinical applications, including the rapid development of drug resistance within several months, less desirable response rates in many solid tumors, and normal tissue toxicity that has been broadly reported (Pratilas and Solit 2010; Caunt et al. 2015; Zhao and Adjei 2014).”
Vural, B. E., & Yandım, C. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.141329 · Cited by 1
Mao, Y., You, Q., Dou, W., Xia, Y., Shi, X., Zhou, J., Dang, C., Bai, J., Li, J., Chen, G., et al. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.115391 · Cited by 1
Lin, C., Li, S., Liang, Y., Zhou, H., Xiao, Z., Yang, Z., Chen, Q., Peng, X., Li, K., Wang, Q., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1595907 · Cited by 3
O-aminobenzamide: An increasingly popular privileged scaffold in drug discovery
Zhuo, L., Xiong, H., Zhang, X., Kim, G.-Y., Peng, Y., Zou, H., Jang, H., Li, J., Wang, Z., & Kim, J. S. (2025) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2025.217231 · Cited by 3
Wu, S., Yao, C., Fang, L., Sun, Y., Zhao, M., Chen, J., Hu, G., Zhao, Z., Ding, S., Xue, J., et al. (2025) · Research · doi:10.34133/research.0998 · Cited by 1
“According to the KEGG pathway analysis, we found that per-oxisome, which is involved in multiple metabolic processes, including fatty acid oxidation and ROS metabolism [ 19 ], was a significantly enriched pathway of interest (Fig.”
Metadata
- Authors
- Caunt, C. J., Sale, M. J., Smith, P. D., & Cook, S. J.
- Affiliations
- University of Bath (GB)
- Babraham Institute (GB)
- AstraZeneca (United Kingdom) (GB)
- Corresponding author
- Smith, Paul D.
- Cook, Simon J.
- Venue
- Nature Reviews Cancer
- Published
- 2015-09-24
- Volume
- 15
- Issue
- 10
- Pages
- 577-592
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W1848470479
- Cited by
- 606
- References
- 201
- Citations by year
- 2026: 27 · 2025: 44 · 2024: 61 · 2023: 48 · 2022: 69 · 2021: 73 · 2020: 47 · 2019: 62 · 2018: 70 · 2017: 66 · 2016: 33 · 2015: 4
- FWCI
- 5.65
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature reviews. Cancer (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Cancer Research UK (14867)
- Biotechnology and Biological Sciences Research Council (BBS/E/B/0000C199, BBS/E/B/000C0417, BBS/E/B/0000H248, BBS/E/B/000C0419, BBS/E/B/0000H151)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Keywords
- MEK1 inhibitor, ERK signaling, Raf/MEK/ERK pathway, BRAF mutation, RAS mutations, Raf-1, drug resistance mechanisms, carcinogenesis, cancer therapy
- MeSH terms
- Humans, Neoplasms, Signal Transduction, MAP Kinase Signaling System, Protein Kinase Inhibitors, MAP Kinase Kinase 1, MAP Kinase Kinase 2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.